Polatuzumab
Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin , which has anti-tumor activity[1].
Product Specifications
CAS Number
2279068-37-8
UNSPSC
12352203
Target
ADC Antibody; Transmembrane Glycoprotein
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/polatuzumab.html
Purity
99.69
Solubility
H2O
Smiles
[Polatuzumab]
Molecular Weight
(145.5 kDa)
References & Citations
[1]Estelle Bourbon, et al. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. Expert Opin Investig Drugs. 2020 Oct;29 (10) :1079-1088.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
TRC-B211000-2G 2 g
Benzyl 2-Acetamido-4,6-O-benzylidene-2-deoxy-a-D-glucopyranoside
Sign In for Pricing
View Details 
BNC401988-500 1x 500 µL
ENAH / MENA (Actin Regulator) (ENAH/1988), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 